Tarsus to Participate at Upcoming Virtual Investor Conferences

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. TARS, whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following virtual investor conferences:

• Ophthalmology Day at BTIG on Tuesday, November 30, 2021
• Piper Sandler 33^rd Annual Virtual Healthcare Conference on December 1-2, 2021

The above listed dates are subject to change. Please check www.tarsusrx.com for the latest information.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.

Contacts:

Media Contact:

SuJin Oh

Shop PR

(917) 841-5213

sujin@shop-pr.com

Investor Contact:

David Nakasone

Head of Investor Relations

(949) 620-3223

DNakasone@tarsusrx.com